凯美特气(002549) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 123.99 million, a decrease of 31.67% compared to CNY 181.47 million in the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 24.20 million, representing a decline of 173.80% from a profit of CNY 32.80 million in the previous year[4]. - The basic earnings per share for Q3 2023 was -CNY 0.036, down 168.44% from CNY 0.0526 in the same period last year[5]. - Total operating revenue for Q3 2023 was CNY 418,463,388.79, a decrease of 23.2% compared to CNY 544,881,763.80 in the same period last year[28]. - Net profit for Q3 2023 was a loss of CNY 15,786,464.74, compared to a profit of CNY 116,627,748.47 in Q3 2022, representing a significant decline[30]. - Basic earnings per share for Q3 2023 was -0.023, compared to 0.1852 in the same quarter last year[30]. Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 2.87 billion, an increase of 28.37% from CNY 2.24 billion at the end of the previous year[5]. - The company's total assets reached CNY 2,871,057,678.99, an increase of 28.5% from CNY 2,236,521,235.70 year-on-year[27]. - Total liabilities decreased to CNY 896,665,022.70, down 10.3% from CNY 998,992,429.85 in the previous year[27]. - The equity attributable to shareholders of the parent company increased to CNY 1,971,051,355.75, up 60% from CNY 1,233,791,570.34 year-on-year[27]. Cash Flow - The company's cash flow from operating activities for Q3 2023 was CNY 184.62 million, an increase of 37.57% compared to CNY 134.20 million in the same period last year[5]. - Net cash flow from operating activities was 184.62 million yuan, an increase of 37.57% year-on-year, primarily due to a decrease in cash received from sales and a decrease in cash paid for purchases[16]. - Net cash flow from investing activities was -711.85 million yuan, an increase of 229.35% year-on-year in net outflow, mainly due to increased cash payments for fixed asset purchases[17]. - Net cash flow from financing activities was 595.53 million yuan, an increase of 189.42% year-on-year, primarily due to funds raised from issuing shares and employee equity incentives[17]. Investments and Projects - The company has made significant investments in new projects, including a CNY 6.45 million increase in the tail gas recovery project for the caprolactam industry chain[9]. - The company plans to invest CNY 693,178,873.73 in the construction of new gas projects, including a 300,000 tons/year high-purity hydrogen peroxide project[22]. - The company has utilized CNY 36,867,800 of raised funds to replace pre-invested project funds, complying with relevant regulations[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,900[19]. - The company completed a private placement of 71,647,901 shares at a price of 9.77 RMB per share, raising a total of 699,999,992.77 RMB after deducting issuance costs of 6,821,119.04 RMB[21]. - As of September 30, 2023, the top 10 shareholders include Haoxun Technology Co., Ltd. with 259,861,273 shares, accounting for a significant portion of the company's equity[20]. - The company has a diverse shareholder base, with significant holdings from various investment firms and insurance companies[20]. Expenses - Sales expenses for the current period were 29.70 million yuan, an increase of 31.66% year-on-year, primarily due to new equity incentive expenses included in sales expenses[12]. - Management expenses for the current period were 89.51 million yuan, an increase of 54.04% year-on-year, mainly due to new equity incentive expenses included in management expenses[13]. - Research and development expenses for the quarter were CNY 29,427,949.29, slightly down from CNY 31,615,914.45 in Q3 2022[28]. Other Financial Metrics - The company reported a total of CNY 1.63 million in non-recurring gains and losses for the current period, down from CNY 8.89 million for the year-to-date period[6]. - The company's inventory decreased to CNY 58,943,403.84 from CNY 69,081,219.85, reflecting a reduction in stock levels[25]. - The company's accounts receivable at the end of Q3 2023 was CNY 60.61 million, a decrease of 59.26% from CNY 148.76 million at the beginning of the year[8].